Vilija G Jokubaitis1, Vivien Li, Tomas Kalincik, Guillermo Izquierdo, Suzanne Hodgkinson, Raed Alroughani, Jeannette Lechner-Scott, Alessandra Lugaresi, Pierre Duquette, Marc Girard, Michael Barnett, Francois Grand'Maison, Maria Trojano, Mark Slee, Giorgio Giuliani, Cameron Shaw, Cavit Boz, Daniele L A Spitaleri, Freek Verheul, Jodi Haartsen, Danny Liew, Helmut Butzkueven. 1. From the Department of Medicine (V.G.J., T.K., H.B.), Melbourne Brain Centre (RMH), The University of Melbourne; Department of Neurology (V.G.J., V.L., T.K., H.B.), Royal Melbourne Hospital, Australia; Hospital Universitario Virgen Macarena (G.I.), Seville, Spain; Liverpool Hospital (S.H.), New South Wales, Australia; Amiri Hospital (R.A.), Kuwait City, Kuwait; John Hunter Hospital (J.L.-S.), Newcastle, Australia; MS Center (A.L.), Department of Neuroscience and Imaging, University "G. d'Annunzio," Chieti, Italy; Hôpital Notre Dame (P.D., M.G.), Montreal, Canada; Brain and Mind Research Institute (M.B.), Sydney, Australia; Neuro Rive-Sud (F.G.), Hôpital Charles LeMoyne, Quebec, Canada; Department of Basic Medical Sciences (M.T.), Neuroscience and Sense Organs, University of Bari, Italy; Flinders University and Medical Centre (M.S.), Adelaide, Australia; Ospedale di Macerata (G.G.), Italy; Geelong Hospital (C.S.), Australia; Karadeniz Technical University (C.B.), Trabzon, Turkey; AORN San Giuseppe Moscati (D.L.A.S.), Avellino, Italy; Groene Hart Ziekenhuis (F.V.), Gouda, the Netherlands; Department of Neurology (J.H., H.B.), Eastern Health Victoria; Monash University (J.H., H.B.), Melbourne; and Melbourne EpiCentre (D.L.), The University of Melbourne and Melbourne Health, Australia.
Abstract
OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse on fingolimod. METHODS: Data were obtained from the MSBase Registry. Relapse rates (RRs) for each patient group were compared using adjusted negative binomial regression. Survival analyses coupled with adjusted Cox regression were used to model predictors of time to first relapse on fingolimod. RESULTS: A total of 536 patients (natalizumab-fingolimod [n = 89]; IFN-β/GA-fingolimod [n = 350]; naive-fingolimod [n = 97]) were followed up for a median 10 months. In the natalizumab-fingolimod group, there was a small increase in RR on fingolimod (annualized RR [ARR] 0.38) relative to natalizumab (ARR 0.26; p = 0.002). RRs were generally low across all patient groups in the first 9 months on fingolimod (RR 0.001-0.13). However, 30% of patients with disease activity on natalizumab relapsed within the first 6 months on fingolimod. Independent predictors of time to first relapse on fingolimod were the number of relapses in the prior 6 months (hazard ratio [HR] 1.59 per relapse; p = 0.002) and a gap in treatment of 2-4 months compared to no gap (HR 2.10; p = 0.041). CONCLUSIONS: RRs after switch to fingolimod were low in all patient groups. The strongest predictor of relapse on fingolimod was prior relapse activity. Based on our data, we recommend a maximum 2-month treatment gap for switches to fingolimod to decrease the hazard of relapse. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that RRs are not higher in patients with multiple sclerosis switching to fingolimod from natalizumab compared to those patients switching to fingolimod from other therapies.
OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse on fingolimod. METHODS: Data were obtained from the MSBase Registry. Relapse rates (RRs) for each patient group were compared using adjusted negative binomial regression. Survival analyses coupled with adjusted Cox regression were used to model predictors of time to first relapse on fingolimod. RESULTS: A total of 536 patients (natalizumab-fingolimod [n = 89]; IFN-β/GA-fingolimod [n = 350]; naive-fingolimod [n = 97]) were followed up for a median 10 months. In the natalizumab-fingolimod group, there was a small increase in RR on fingolimod (annualized RR [ARR] 0.38) relative to natalizumab (ARR 0.26; p = 0.002). RRs were generally low across all patient groups in the first 9 months on fingolimod (RR 0.001-0.13). However, 30% of patients with disease activity on natalizumab relapsed within the first 6 months on fingolimod. Independent predictors of time to first relapse on fingolimod were the number of relapses in the prior 6 months (hazard ratio [HR] 1.59 per relapse; p = 0.002) and a gap in treatment of 2-4 months compared to no gap (HR 2.10; p = 0.041). CONCLUSIONS: RRs after switch to fingolimod were low in all patient groups. The strongest predictor of relapse on fingolimod was prior relapse activity. Based on our data, we recommend a maximum 2-month treatment gap for switches to fingolimod to decrease the hazard of relapse. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that RRs are not higher in patients with multiple sclerosis switching to fingolimod from natalizumab compared to those patients switching to fingolimod from other therapies.
Authors: F Castrop; M C Kowarik; H Albrecht; M Krause; B Haslinger; C Zimmer; A Berthele; B Hemmer Journal: Neurology Date: 2012-03-07 Impact factor: 9.910
Authors: Ludwig Kappos; Jack Antel; Giancarlo Comi; Xavier Montalban; Paul O'Connor; Chris H Polman; Tomas Haas; Alexander A Korn; Goeril Karlsson; Ernst W Radue Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245
Authors: Douglas R Jeffery; Clyde E Markowitz; Anthony T Reder; Bianca Weinstock-Guttman; Kathy Tobias Journal: Expert Rev Neurother Date: 2010-12-16 Impact factor: 4.618
Authors: H Butzkueven; J Chapman; E Cristiano; F Grand'Maison; M Hoffmann; G Izquierdo; D Jolley; L Kappos; T Leist; D Pöhlau; V Rivera; M Trojano; F Verheul; J P Malkowski Journal: Mult Scler Date: 2006-12 Impact factor: 6.312
Authors: Ludwig Kappos; David Bates; Gilles Edan; Mefkûre Eraksoy; Antonio Garcia-Merino; Nikolaos Grigoriadis; Hans-Peter Hartung; Eva Havrdová; Jan Hillert; Reinhard Hohlfeld; Marcelo Kremenchutzky; Olivier Lyon-Caen; Ariel Miller; Carlo Pozzilli; Mads Ravnborg; Takahiko Saida; Christian Sindic; Karl Vass; David B Clifford; Stephen Hauser; Eugene O Major; Paul W O'Connor; Howard L Weiner; Michel Clanet; Ralf Gold; Hans H Hirsch; Ernst-Wilhelm Radü; Per Soelberg Sørensen; John King Journal: Lancet Neurol Date: 2011-08 Impact factor: 44.182
Authors: O Stüve; P D Cravens; E M Frohman; J T Phillips; G M Remington; G von Geldern; S Cepok; M P Singh; J W Cohen Tervaert; M De Baets; D MacManus; D H Miller; E W Radü; E M Cameron; N L Monson; S Zhang; R Kim; B Hemmer; M K Racke Journal: Neurology Date: 2008-11-05 Impact factor: 9.910
Authors: Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven Journal: Nat Rev Neurol Date: 2017-01-13 Impact factor: 42.937
Authors: Maria Sepúlveda; Sara Llufriu; Yolanda Blanco; Nuria Solà-Valls; Delon La Puma; Joan Berenguer; Pablo Villoslada; Albert Saiz Journal: J Neurol Date: 2014-11-20 Impact factor: 4.849
Authors: F Esposito; L Ferrè; F Clarelli; M A Rocca; G Sferruzza; L Storelli; M Radaelli; F Sangalli; L Moiola; B Colombo; F Martinelli Boneschi; G Comi; M Filippi; V Martinelli Journal: J Neurol Date: 2018-02-12 Impact factor: 4.849
Authors: P Kolber; F Luessi; S G Meuth; L Klotz; T Korn; C Trebst; B Tackenberg; B Kieseier; T Kümpfel; V Fleischer; H Tumani; B Wildemann; M Lang; P Flachenecker; U Meier; W Brück; V Limmroth; A Haghikia; H-P Hartung; M Stangel; R Hohlfeld; B Hemmer; R Gold; H Wiendl; F Zipp Journal: Nervenarzt Date: 2015-10 Impact factor: 1.214